Peters Hannah L, Jochmans Dirk, de Wilde Adriaan H, Posthuma Clara C, Snijder Eric J, Neyts Johan, Seley-Radtke Katherine L
University of Maryland, Baltimore County, Department of Chemistry & Biochemistry, 1000 Hilltop Circle, Baltimore, MD 21250, USA.
Rega Institute, University of Leuven (KULeuven), Minderbroederstraat 10, Leuven BE-3000, Belgium.
Bioorg Med Chem Lett. 2015 Aug 1;25(15):2923-6. doi: 10.1016/j.bmcl.2015.05.039. Epub 2015 May 23.
A series of doubly flexible nucleoside analogues were designed based on the acyclic sugar scaffold of acyclovir and the flex-base moiety found in the fleximers. The target compounds were evaluated for their antiviral potential and found to inhibit several coronaviruses. Significantly, compound 2 displayed selective antiviral activity (CC50 >3× EC50) towards human coronavirus (HCoV)-NL63 and Middle East respiratory syndrome-coronavirus, but not severe acute respiratory syndrome-coronavirus. In the case of HCoV-NL63 the activity was highly promising with an EC50 <10 μM and a CC50 >100 μM. As such, these doubly flexible nucleoside analogues are viewed as a novel new class of drug candidates with potential for potent inhibition of coronaviruses.
基于阿昔洛韦的无环糖骨架和柔性核苷中发现的柔性碱基部分,设计了一系列双柔性核苷类似物。对目标化合物的抗病毒潜力进行了评估,发现它们能抑制多种冠状病毒。值得注意的是,化合物2对人冠状病毒(HCoV)-NL63和中东呼吸综合征冠状病毒表现出选择性抗病毒活性(CC50>3×EC50),但对严重急性呼吸综合征冠状病毒没有活性。就HCoV-NL63而言,其活性非常有前景,EC50<10μM,CC50>100μM。因此,这些双柔性核苷类似物被视为一类新型的候选药物,具有有效抑制冠状病毒的潜力。